Study of single nucleotide polymorphism of SOCS gene in typical myeloproliferative neoplasms.
10.7534/j.issn.1009-2137.2013.06.026
- Author:
Wei QIN
1
;
Tao CHEN
1
;
Jian-He YANG
1
;
Yan ZHANG
1
;
Rong XIAO
1
;
Jing-Tao LU
1
;
Ting WANG
1
;
Min ZHOU
2
;
Jin-Yuan HE
1
Author Information
1. Department of Hematology, The Second Hospital of Changzhou, Nanjing Medical University, Changzhou 213000, China.
2. Department of Hematology, The Second Hospital of Changzhou, Nanjing Medical University, Changzhou 213000, China. E-mail:zhoumin@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Exons;
Female;
Humans;
Male;
Middle Aged;
Mutation;
Myeloproliferative Disorders;
genetics;
Polymorphism, Single Nucleotide;
Suppressor of Cytokine Signaling 1 Protein;
Suppressor of Cytokine Signaling 3 Protein;
Suppressor of Cytokine Signaling Proteins;
genetics;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(6):1507-1512
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the effect of mutation and single nucleotide polymorphism (SNP) of suppressor of cytokine signaling (SOCS) on the typical myeloproliferative neoplasms (MPN) and its mechanism. The mutation and SNP of SOCS1, SOCS2, SOCS3 genes in 100 MPN patients were detected by RT-PCR and direct sequencing. The results showed that among 100 cases there were 21 cases with A→C polymorphism in the 63th site nucleotide of the 15 SOCS3 exon (SNP library no reported), 18 cases with A→C polymorphism in the 1779th site nucleotide of the 15 SOCS3 exon, 49 cases with A→G polymorphism in the 2249th site nucleotide of the 15 SOCS3 exon (SNP library no reported), 39 cases with T→C polymorphism in the 2366th site nucleotide of the 15 SOCS3 exon (SNP library no reported), 9 cases with T→C polymorphism in the exon of 15 SOCS2 gene (SNP library no reported). SOCS3 SNP was found in patients with significantly advanced age at diagnosis, the leukocyte count and platelet level were higher than those in patients with wild type, JAK2V617 mutations was found in 87.65% SOCS3 SNP. It is concluded that the SOCS may be an important target for anticancer therapy, the single nucleotide polymorphism of SOCS may involve to pathogenesis of MPN.
